Clinical Trials
3 trialsNCT05212701 2024-04-30
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
DompƩ Farmaceutici S.p.A
Phase 2 Withdrawn
NCT02370238 2022-09-16
FRIDA
DompƩ Farmaceutici S.p.A
Phase 2 Completed
NCT01861054 2021-05-14
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
DompƩ Farmaceutici S.p.A
Phase 2 Terminated